期刊
HYPERTENSION RESEARCH
卷 31, 期 8, 页码 1583-1588出版社
SPRINGERNATURE
DOI: 10.1291/hypres.31.1583
关键词
nattokinase; blood pressure; renin activity; randomized; controlled trial
资金
- Japan Bio Science Laboratory Co., Ltd., Ibaraki, Osaka, Japan [R0A-2005-000-10144-0]
- Ministry of Education, Science and Technology, Korea
- Korea Science and Engineering Foundation (KOSEF)
- Ministry of Education, Science and Technology, Korea [M10642120002-06N4212-00210]
The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension. (Hypertens Res 2008; 31: 1583-1588)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据